site:pharmaphorum.com - Search Images

2133 x 1600 · jpeg
deep-dive.pharmaphorum.com
Timeline: a history of medical imaging - pharmaphorum
5616 x 3744 · jpeg
pharmaphorum.com
Europe has its first Lucentis biosimilar, Samsung Bioepis' Byooviz ...
1698 x 1131 · jpeg
pharmaphorum.com
AstraZeneca ‘probably couldn’t run Gilead any better:’ analyst
1600 x 1200 · jpeg
pharmaphorum.com
Belgium's eTheRNA gets EU grant to develop mRNA cancer vaccines

1200 x 675 · jpeg
pharmaphorum.com
Reuters: Pharma 2022 | pharmaphorum
1600 x 900 · jpeg
pharmaphorum.com
Pharma waste management: Balancing cost, compliance, and environmental ...
960 x 540 · jpeg
pharmaphorum.com
BMS wagers $14bn on Karuna’s schizophrenia drug | pharmaphorum

960 x 540 · jpeg
pharmaphorum.com
Biogen bets $1.15bn on immunology drug developer HI-Bio | pharmaphorum
1600 x 900 · jpeg
pharmaphorum.com
How pharma can improve regulatory compliance with AI-based technology ...
2362 x 1771 · jpeg
pharmaphorum.com
New strategies for stakeholder engagement in life sciences | …
1698 x 1131 · jpeg
pharmaphorum.com
$2bn deal sees uniQure license haemophilia B gene therapy to CS…

960 x 540 · jpeg
pharmaphorum.com
Amgen preps Uplizna filing for a second indication | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Change at the top at Recipharm as strategy shifts | pharmaphorum
1600 x 1200 · jpeg
pharmaphorum.com
Still too little progress on antibiotic resistance, says O’…
960 x 540 · jpeg
pharmaphorum.com
AstraZeneca throws its hat into the oral PCSK9 ring | pharmaphorum

900 x 600 · jpeg
pharmaphorum.com
Boehringer recruits former Novartis' neurosciences head a…
840 x 473 · jpeg
pharmaphorum.com
Taking the right forecasting approach for rare diseases | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Adcendo licenses Multitude anti-TF ADC in $1bn+ deal | pharmaphorum
1600 x 900 · jpeg
pharmaphorum.com
BIOSECURE Act clears House vote | pharmaphorum

960 x 540 · jpeg
pharmaphorum.com
GSK raises forecasts for 2024, but shares slide | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Novo Nordisk tackles supply issues with $11bn Catalent deal | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Deep Dive: Patients and Partnerships 2022 | pharmaphorum

1600 x 900 · jpeg
pharmaphorum.com
South Korea: Emerging global leader in life sciences | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
PBC drug choices rise in US with OK for Gilead's seladelpar | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
GSK says $2.2bn settlement resolves most Zantac litigation | pharmaphorum

960 x 540 · jpeg
pharmaphorum.com
Lilly says tirzepatide staves off diabetes in phase 3 trial | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
BenevolentAI CEO steps down as founders make a comeback | pharmaphorum
1600 x 900 · jpeg
pharmaphorum.com
Top 5 pharma marketing trends in 2024 | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
Australia joins EU in turning down Alzheimer's drug Leqembi | pharmaph…
900 x 600 · jpeg
pharmaphorum.com
Novo Nordisk launches recycling programme for pen injectors | p…
1600 x 900 · jpeg
pharmaphorum.com
Threats impacting the pharmaceutical industry in 2024 | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
FDA clears Ipsen’s primary biliary cholangitis drug | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
Gilead, MSD say HIV combo could be weekly, oral HIV drug | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
NIH study backs Bavarian Nordic mpox jab for adolescents | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Astellas strikes $1.7bn SIRP drug deal with Elpiscience | pharmaphorum

Some results have been hidden because they may be inaccessible to you.Show inaccessible results